KOSDAQBiotech & Pharma214260

Raphas

₩7,560▲ 3.00%2026-11-18 close
Market Cap
₩67.5B
Turnover
₩89,631,030
Volume
10K
Shares out.
8.9M
PER
—
PBR
2.9×
EPS
-₩917
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Losses narrowing as pipeline moves toward clinical stage

Raphas has grown revenue and narrowed its operating loss over the reported years, but the net loss attributable to controlling shareholders widened to KRW 3.66 billion in Q3 2026, so the sustainability of the recovery remains unproven.

  1. 1

    Annual revenue rose from KRW 23.6 billion in 2022 to KRW 31 billion in 2025, the largest year in the 2022–2025 period.

  2. 2

    The operating loss narrowed from KRW 6.55 billion in 2022 to KRW 3.03 billion in 2025, and the operating margin improved from -27.7% to -9.8%.

  3. 3

    The Q3 2026 net loss attributable to controlling shareholders of KRW 3.66 billion was larger than both the prior quarter and the year-earlier quarter, and the last four quarters total KRW 7.96 billion.

  4. 4

    The allergic rhinitis immunotherapy patch DF19001 filed a Phase 2b/3 trial plan in May 2026, and the obesity patch DW-1022 completed a domestic Phase 1 trial.

  5. 5

    At year-end 2025, total liabilities were KRW 44.4 billion against total equity of KRW 30.7 billion, a debt ratio of 144.4%.

02

Business structure

Raphas, founded in 2006 and listed on KOSDAQ in 2019, is a transdermal drug delivery (TDDS) specialist. Its core product is dissolving microneedle patches built on its proprietary DEN technology, and it handles research, manufacturing and sales in-house.

The DEN process deposits drug droplets without molds and dries them at room temperature with air flow, avoiding heating steps that can denature bio-active ingredients. Revenue is centered on cosmetics, and according to IB Tomato, microneedles accounted for 88.37% of standalone sales in the year reported.

Within cosmetics, ODM and own-brand sales both contribute, and the company exports beauty patches to the United States, China and Japan through local subsidiaries.

Consolidated subsidiaries include PostBio, a research reagent developer, and Edaily reported that core pipeline subsidiaries such as PostBio lifted revenue in the first nine months of 2025. On the pharmaceutical side, the company is prioritizing prescription drugs that replace injectables and vaccine patches.

Its lead programs are the allergic rhinitis immunotherapy patch DF19001, which completed Phase 1 in December 2025, and the semaglutide obesity patch DW-1022. In competition, a domestic microneedle startup differs from Raphas in its manufacturing process.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩9.6B-₩600M−6.7%
2025Q4₩6.2B-₩1B−15.8%
2026Q1₩6.8B-₩500M−7.6%
2026Q2₩7.6B-₩1.8B−23.3%
2026Q3₩7.7B-₩1.4B−17.9%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩23.6B-₩6.6B-₩8.5B−27.7%−20.8%118.3%
2023₩27.9B-₩4.1B-₩8.8B−14.5%−29.8%210.8%
2024₩27.2B-₩3.5B-₩4.8B−12.7%−16.3%140.6%
2025₩31B-₩3B-₩4.3B−9.8%−15.2%144.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

On a reported basis, annual revenue was KRW 23.6 billion in 2022, KRW 27.9 billion in 2023 (up 18.2% year on year), KRW 27.2 billion in 2024 (down 2.6%) and KRW 31 billion in 2025 (up 13.9%). 2025 was the largest year of 2022–2025 and 2022 the smallest.

The operating loss was KRW 6.55 billion in 2022, KRW 4.05 billion in 2023, KRW 3.46 billion in 2024 and KRW 3.03 billion in 2025, a continuing loss each year with a smaller gap every year, and the operating margin improved from -27.7% to -9.8%.

The net loss attributable to controlling shareholders was KRW 8.51 billion in 2022, KRW 8.8 billion in 2023 (a wider loss), KRW 4.77 billion in 2024 and KRW 4.31 billion in 2025.

Net loss including non-controlling interests, a different figure, was KRW 8.63 billion, KRW 9.25 billion, KRW 5.8 billion and KRW 4.74 billion over the same years. The debt ratio went from 118.3% in 2022 to 210.8% in 2023 before settling at 140.6% in 2024 and 144.4% in 2025.

Operating cash flow moved from -KRW 3.63 billion in 2022 and -KRW 1.81 billion in 2023 to KRW 4.88 billion in 2024 and KRW 1.43 billion in 2025.

Quarterly revenue fell from KRW 9.6 billion in Q3 2025 to KRW 6.21 billion in Q4 2025 (down 35.3% quarter on quarter), then rose to KRW 6.77 billion in Q1 2026, KRW 7.58 billion in Q2 2026 and KRW 7.75 billion in Q3 2026, three straight quarterly gains. Still, Q3 2026 revenue was down 19.3% from a year earlier.

The operating loss was KRW 645 million in Q3 2025, KRW 982 million in Q4 2025, KRW 517 million in Q1 2026, KRW 1.77 billion in Q2 2026 and KRW 1.38 billion in Q3 2026, so Q3 2026 narrowed from the prior quarter but widened from a year earlier.

The Q3 2026 net loss attributable to controlling shareholders of KRW 3.66 billion was far larger than the operating loss, which points to non-operating items as the driver and makes that line the thing to examine in the filing.

For the first nine months of 2025, Edaily reported that a decline in non-operating losses such as convertible bond valuation losses narrowed the net loss.

05

Industry analysis

In transdermal drug delivery, microneedles move with demand for alternatives to injectable drugs.

Raphas has put prescription drugs that replace injectables and vaccine patches at the center of its direction, so successful development could change a revenue structure that is currently cosmetics-led, and that is the bull argument often raised.

Development of prescription drugs, however, depends heavily on clinical outcomes and licensing negotiations.

In competition, a domestic microneedle startup has raised KRW 3.3 billion in an investment round to strengthen mass-production capacity, and Sisajournal reported clear technical differences in microneedle manufacturing between the two.

Raphas's DEN process avoids heating steps, which is aimed at reducing losses of costly bio-ingredients. Cosmetic patch sales are exposed to consumer spending and changes in distribution channels, and the company's earnings commentary says globalizing products and sales channels is reducing exposure to economic swings.

Compared with large listed biopharma names such as Samsung Biologics and Celltrion, Raphas is smaller in revenue and financial scale, and its business structure differs from Alteogen, which is cited as a comparison on drug delivery formulation technology.

The benchmarks for judging the sector are the pace of clinical entry, expansion of overseas channels and the stability of cosmetics revenue.

06

Outlook

The nearest scheduled check on reported figures is the 2026 annual report.

Q1 2026 revenue was down 4.2% from a year earlier on a consolidated basis, and although quarterly revenue rose through Q3, Q3 2026 revenue of KRW 7.75 billion was still down 19.3% from the year-earlier quarter, so a return to prior-year levels has not yet appeared.

Q2 2026 revenue came in below the forecast aggregated by investing.com. On the pipeline side, DF19001 filed a Phase 2b/3 trial plan in May 2026, and whether the trial starts after approval is a fact the next disclosures will show.

A recent press report raised technology licensing and a Phase 2 push for DW-1022, and whether a deal is signed remains the largest open variable. When the first nine months of 2025 were reported, a company official said the company was pairing competitiveness in core pipelines with strict cost control.

Whether that cost discipline carries into the operating loss trend in 2026 quarters is the point to check. In the 2026 annual report, the key items will be whether the operating margin improves again and how the non-operating components of the net loss attributable to controlling shareholders change.

07

Valuation

PER
—
PBR
2.9×
ROE
-30.5%
EPS
-₩917
BPS
₩2,632
Dividend per share
₩0

Because the last four quarters were all net losses, the price-to-earnings ratio cannot be calculated. The price-to-book ratio sits in the zone of a premium over net asset value, with market capitalization above the equity attributable to controlling shareholders.

That can be read as the market pricing in pipeline and technology value beyond book assets, or as a premium that is hard to sustain without a profit recovery, and both readings coexist. Dividend history is not pronounced, so dividends offer little support to the share price.

Sector multiple comparisons do not work on earnings for a loss-making company and are only possible on price-to-book. The 144.4% debt ratio and the 45.4% borrowing dependence reported by IB Tomato indicate financial burden, which is raised as a discount factor in valuation discussions.

Whether the narrowing loss trend continues, and how much the net loss attributable to controlling shareholders moves with non-operating items, will shift the weight of any valuation reading.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Revenue momentum and a narrowing loss

Revenue reached KRW 31 billion in 2025, up 13.9% from a year earlier, and quarterly revenue rose for three straight quarters from Q1 through Q3 2026. Over the same period the operating loss narrowed from KRW 6.55 billion in 2022 to KRW 3.03 billion in 2025. Room for margin improvement depends on whether revenue growth and cost control continue together.

Pipeline moving into clinical stages

The allergic rhinitis immunotherapy patch DF19001 completed Phase 1 in December 2025 and filed a Phase 2b/3 trial plan in May 2026. The obesity patch DW-1022 completed a domestic Phase 1 trial, and a press report said technology licensing and a Phase 2 trial are being pursued.

If the injectable-replacement direction is borne out by clinical results, the scope of the business could widen.

Proprietary process and overseas channels

The DEN process dries patches at room temperature without molds or heating steps. Beauty patches are exported to the United States, China and Japan through local subsidiaries, which gives the company an overseas channel base. Operating cash flow stayed positive at KRW 4.88 billion in 2024 and KRW 1.43 billion in 2025.

09

Bear factors

Wider losses in Q3 2026

The Q3 2026 net loss attributable to controlling shareholders of KRW 3.66 billion was larger than both the prior quarter and the year-earlier quarter. The last four quarters total KRW 7.96 billion.

Q3 2026 revenue was down 19.3% from a year earlier, so quarterly gains have not yet translated into a return to prior-year revenue.

Shrinking equity and financial burden

At year-end 2025, total liabilities were KRW 44.4 billion against total equity of KRW 30.7 billion, a 144.4% debt ratio. IB Tomato reported that continuing losses turned retained earnings into an accumulated deficit from 2024. The same report put borrowing dependence at 45.4%.

Revenue concentration and loss structure

According to an IB Tomato report, 88.37% of standalone sales came from the microneedle segment, which means revenue is concentrated in one business. Q1 2026 revenue was down 4.2% from a year earlier, and Q2 2026 revenue came in below the forecast aggregated by investing.com.

10

Risk factors

Clinical and licensing risk

No timing has been disclosed for DF19001 entering its Phase 2b/3 trial, and neither the timing nor the terms of a DW-1022 licensing deal have been confirmed. Delays or weak results could lower expectations for the pipeline.

Prescription drug development is highly sensitive to stage-by-stage outcomes, so when it reaches earnings is uncertain.

Balance sheet risk

Total liabilities of KRW 44.4 billion exceed total equity of KRW 30.7 billion, a debt ratio of 144.4%. Because accumulated losses have turned retained earnings into a deficit, equity may keep shrinking. Operating cash flow stayed positive, but at a modest scale, leaving limited room for debt repayment.

Concentration and cyclical exposure

Most sales come from the microneedle segment, and cosmetic revenue is exposed to consumer spending and changes in distribution channels. Competition in manufacturing processes with a domestic microneedle startup continues. Whether overseas subsidiaries broaden channels enough to reduce this concentration is the point to watch.

11

What to watch next

  1. Late March 2027

    The 2026 annual report will confirm full-year revenue and operating loss, along with the Q4 2026 net loss attributable to controlling shareholders. It is also the place to check what drove non-operating losses and how the debt ratio changed.

  2. Mid-May 2027

    This is the Q1 2027 earnings release. Q1 2026 results came out on May 15, so this timing is the reference point. Watch whether revenue growth continues and whether the operating loss returns to the Q2 2026 level.

  3. Timing not disclosed (after trial approval)

    Approval of the DF19001 Phase 2b/3 trial plan and the start of first-patient dosing. Once the trial begins, it becomes the first objective marker for judging pipeline value.

  4. Timing not disclosed

    Whether a DW-1022 technology licensing deal is signed and the Phase 2 trial begins. The deal terms and counterparty disclosures will be the basis for judging any change in business structure.

12

Overall view

Between 2022 and 2025, Raphas grew revenue from KRW 23.6 billion to KRW 31 billion and narrowed its operating loss from KRW 6.55 billion to KRW 3.03 billion, a direction of improving economics.

However, the net loss attributable to controlling shareholders widened to KRW 3.66 billion in Q3 2026, bringing the last four quarters to KRW 7.96 billion, and the 144.4% debt ratio remains a burden.

Bull factors are three straight quarters of revenue growth, a pipeline moving into clinical stages, and overseas channels in the United States, China and Japan. Bear factors are wider quarterly net losses, concentration in the microneedle segment and shrinking equity.

The value of the pipeline depends on clinical results and licensing, and that stage has not yet been confirmed in filings. In the 2026 annual report, the continuation of margin improvement and the composition of non-operating items behind the net loss are the key points to check.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 15 more articles and sources
  1. comp.wisereport.co.kr
  2. m.jobkorea.co.kr
  3. comp.wisereport.co.kr
  4. newstomato.com
  5. investing.com
  6. thinkpool.com
  7. investing.com
  8. m.saramin.co.kr
  9. sisajournal-e.com
  10. comp.fnguide.com
  11. kr.investing.com
  12. edaily.co.kr
  13. paxetv.com
  14. pharm.edaily.co.kr
  15. tradingkey.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis